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Merkel cell carcinoma is a polyoma-
virus-driven skin cancer (Feng et al.,
2008) that is three times more likely to
be lethal than malignant melanoma
(Lemos and Nghiem, 2007). We have
found that survival following diagnosis
of this cancer is strongly linked to
cellular immune function, with intra-
tumoral CD8þ T-cell infiltration into
the tumor providing remarkable protec-
tion from subsequent recurrence/death,
even among patients who present with
advanced disease (Paulson et al., 2011).
The observation that antibodies to the
Merkel polyomavirus oncoprotein fluc-
tuate with disease burden is the basis
for a blood test (clinically available
as of 2014; www.merkelcell.org/sero)
for detecting early disease recurrence
(Paulson et al., 2010). The identifi-
cation and reversal of immune evasion
mechanisms of this cancer are the focus
of several clinical trials led by members
of an international collaborative group
(www.merkelcell.org/MMIG). The Seattle
team follows over 1000 patients with this
cancer for outcomes and clinical trials.
Ongoing multidisciplinary investigations
span molecular, cellular, and human
in vivo studies. Several currently active
and planned clinical trials are designed to
increase the number and function of
CD8þ T cells that are specific for
Merkel cell polyomavirus proteins. Such
T cells are typically present in patients
with this cancer, but are frequently
‘exhausted’ (Afanasiev et al., 2013) and
therefore not able to control tumor
growth. Reactivating such T-cell res-
ponses by reversing exhaustion is feasi-
ble and may be therapeutically beneficial
for this aggressive skin cancer.
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